KR900009096A - 이(2)특이적 단클론성 항체, 그의 제조방법 및 용도 - Google Patents

이(2)특이적 단클론성 항체, 그의 제조방법 및 용도 Download PDF

Info

Publication number
KR900009096A
KR900009096A KR1019890019722A KR890019722A KR900009096A KR 900009096 A KR900009096 A KR 900009096A KR 1019890019722 A KR1019890019722 A KR 1019890019722A KR 890019722 A KR890019722 A KR 890019722A KR 900009096 A KR900009096 A KR 900009096A
Authority
KR
South Korea
Prior art keywords
group
antigen
derivative
monoclonal antibody
ansamitocin
Prior art date
Application number
KR1019890019722A
Other languages
English (en)
Inventor
스스무 이와사
가오리 하라다
유끼오 도요다
Original Assignee
우메모또 요시마사
다께다야꾸힝 고오교 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 우메모또 요시마사, 다께다야꾸힝 고오교 가부시끼가이샤 filed Critical 우메모또 요시마사
Publication of KR900009096A publication Critical patent/KR900009096A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6861—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from kidney or bladder cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
    • A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/14—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from fungi, algea or lichens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3038—Kidney, bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/972—Modified antibody, e.g. hybrid, bifunctional

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음.

Description

이(2)특이적 단클론성 항체, 그의 제조방법 및 용도
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 실시예 1에서 제조한 항-ANS 항체 AS6-44.9를 참고예 1에 기재된 ELISA 방법에 따라 수행시킴으로써 수득한 항체 희석곡선을 나타낸다.
제2도는 ANS(1ng/ml)에 대한 동일한 AS6-44.9항체의 중화활성 곡선을 나타낸다.
제3도는 실시예 2에서 제조한 하이브리드항체 ATF1-170의 이(2)특이적 항체활성을 나타낸다.

Claims (24)

  1. 안사미토신 유도체 및 목적 항원 모두에 결합 친화력을 가짐을 특징으로하는 하이브리드 단클론성 항체.
  2. 제1항에 있어서, 목적 항원이 종양-연관 항원인 하이브리드 단클론성 항체.
  3. 제2항에 있어서, 종양-연관 항원이 인간 트란스페린 수용기인 하이브리드 단클론성 항체.
  4. 제2항에 있어서, 종양-연관 항원이 인간 신장 세포 육종-연관 당단백질인 하이브리드 단클론성 항체.
  5. 제1항에 있어서, 안사미토신 유도체가 하기 일반식(I)의 화합물 또는 그의 4, 5-데옥시 유도체인 하이브리드 단클론성 항체.
    [상기 식중, R은 수소 원자 또는 카르복실산으로부터 유도된 아실기를 나타내고 Q는 수산기 또는 메르캅토기를 나타내고, X는 염소 원자 또는 수소 원자를 나타내고, Y는 수소원자, 저급 알킬술포닐기, 알킬기 또는 아르알킬기(알킬 및 아르알킬기는 치환되거나 또는 치환되지 않는다)를 나타낸다.]
  6. 제5항에 있어서, R이 하기 일반식(II)의기 또는 하기 일반식(III)의기를 나타내는 하이브리드 단클론성 항체.
    [상기 식중, R1은 1~18탄소 원자를 갖는 알킬기를 나타내고, R2, R3및 R4은 1~18탄소 원자를 갖는 알칼기를 나타내고, Q는 수산기 또는 메르캅토기를 나타내고, X는 염소 원자를 나타내고, Y는 1~8탄소 원자를 갖는 알킬기를 나타낸다.]
  7. 안사미토신 유도체 및 목적항원 모두에 결합 친화력을 가짐을 특징으로하는, 안사미토신 유도체와 하이리 브리드 단클론성 항체와의 면역착체.
  8. 제7항에 있어서, 목적 항원이 종양-연관 항원인 면역착체.
  9. 제8항에 있어서, 종양-연관항원이 인간 트란스페린 수용기인 면역착체.
  10. 제8항에 있어서, 종양-연관 항원이 인간 신장 세포육종-연관 당단백질인 면역착체.
  11. 제7항에 있어서, 안사미토신 유도체가 하기 일반식의 화합물 또는 그의 4,5-데옥시 유도체인 면역착체.
    [상기 식중, R, Q, X 및 Y는 제5항의 정의와 동일하다.]
  12. 제11항에 있어서, R이 하기 일반식(II)의기 또는 하기 일반식(III)의기를 나타내는 면역착체.
    [상기 식중, R1, R2, R3, R4, Q, X 및 Y는 제6항의 정의와 동일하다.]
  13. 제7항에 있어서, 안사미토신 유도체가 안사미토신인 면역착체.
  14. 안사미토신 유도체 및 목적항원 모두에 결합 친화력을 갖는 하이브리드 단클론성 항체를 생성할 수 있음을 특징으로 하는 폴리도마.
  15. 제14항에 있어서, 테트라오마인 폴리도마.
  16. 제14항에 있어서, 목적항원이 종양-연관 항원인 폴리도마.
  17. 제16항에 있어서, 종양-연관 항원이 인간트란스페린 수용기인 폴리도마.
  18. 제16항에 있어서, 종양-연관 항원이 인간 신장세포 육종-연관 당단백질인 폴리도마.
  19. 제14항에 있어서, 안사미토신 유도체가 하기 일반식의 화합물 또는 그의 4,5-데옥시 유도체인 폴리도마.
    [상기 식중, R, Q, X 및 Y는 제5항의 정의와 동일하다.]
  20. 제19항에 있어서, R이 하기 일반식(II)의기 또는 하기 일반식(III)의기를 나타내는 폴리도마.
    [상기 식중, R1, R2, R3, R4, Q, X 및 Y는 제6항의 정의와 동일하다.]
  21. 안사미토신 유도체와 목적항원 모두에 대해 결합 친화력을 갖는 하이브리드 단클론성 항체를 생성할 수 있는 폴리도마를 배양하고 배양액으로부터 상기 하이브리드 단클론성 항체를 회수함을 특징으로하는, 안사미토신 유도체와 목적 항원 모두에 결합 친화력을 갖는 하이브리드 단클론성 항체의 제조방법.
  22. 안사미토신 유도체와 목적 항원 모두에 결합 친화력을 갖는 하이브리드 단클론성 항체를 안사미토신 유도체와 반응시킴을 특징으로하는, 안사미토신 유도체 및 목적 항원 모두에 결합 친화력을 갖는 하이브리드 단클론성 항체와 안사미토신 유도체와 면역착체의 제조방법.
  23. 안사미토신 유도체를 생성할 수 있는 동물 세포와 목적 항원에 대한 항체를 생성할 수 있는 동물 세포를 융합시킴을 특징으로 하는, 안사미토신 유도체와 목적 항원 모두에 결합 친화력을 갖는 하이브리드 단클론성 항체를 생성할 수 있는 폴리도마의 제조방법.
  24. 제23항에 있어서, 상기 동물 세포가 모두 하이브리도마인 제조방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890019722A 1988-12-27 1989-12-27 이(2)특이적 단클론성 항체, 그의 제조방법 및 용도 KR900009096A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP33219488 1988-12-27
JP88-332194 1988-12-27
JP1856089 1989-01-26
JP89-018560 1989-01-26

Publications (1)

Publication Number Publication Date
KR900009096A true KR900009096A (ko) 1990-07-02

Family

ID=26355251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890019722A KR900009096A (ko) 1988-12-27 1989-12-27 이(2)특이적 단클론성 항체, 그의 제조방법 및 용도

Country Status (6)

Country Link
US (1) US5141736A (ko)
EP (1) EP0376176A3 (ko)
KR (1) KR900009096A (ko)
CA (1) CA2006408A1 (ko)
DK (1) DK666389A (ko)
HU (1) HUT53153A (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100497719B1 (ko) * 2002-06-17 2005-06-28 대동공업주식회사 트랙터용 전륜증속 절환용 클러치

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977307A (en) * 1989-09-07 1999-11-02 Alkermes, Inc. Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
US5672683A (en) * 1989-09-07 1997-09-30 Alkermes, Inc. Transferrin neuropharmaceutical agent fusion protein
US6329508B1 (en) 1989-09-07 2001-12-11 Alkermes, Inc. Transferrin receptor reactive chimeric antibodies
CA2026147C (en) * 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) * 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6099842A (en) * 1990-12-03 2000-08-08 The United States Of America As Represented By The Department Of Health And Human Services Recombinant immunotoxin composed of a single chain antibody reacting with the human transferrin receptor and diptheria toxin
US5622835A (en) * 1994-04-28 1997-04-22 The Wistar Institute Of Anatomy & Biology WT1 monoclonal antibodies
US6991907B1 (en) 1995-04-18 2006-01-31 Biosite, Inc. Methods for the assay of troponin I and T and complexes of troponin I and T and selection of antibodies for use in immunoassays
US6627404B1 (en) * 1995-04-18 2003-09-30 Biosite, Inc. Methods for improving the recovery of troponin I and T in membranes, filters and vessels
ATE281648T1 (de) * 1995-04-18 2004-11-15 Biosite Diagnostics Inc Verfahren zum assay von troponin i und t und komplexen von troponin i und t und auswahl von antikörpern zur verwendung in immunoassays
US6015555A (en) * 1995-05-19 2000-01-18 Alkermes, Inc. Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
US6805869B2 (en) 1996-06-12 2004-10-19 Shanghai Cp Guojian Pharmaceutical Co., Ltd. Cellular vaccines and immunotherapeutics and methods for their preparation
US20050136066A1 (en) * 1996-06-12 2005-06-23 Yajun Guo Cellular vaccines and immunotherapeutics and methods for their preparation
WO1999050461A1 (en) * 1998-03-30 1999-10-07 Northwest Biotherapeutics, Inc. Therapeutic and diagnostic applications based on the role of the cxcr-4 gene in tumorigenesis
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
US20020156274A1 (en) * 2001-03-16 2002-10-24 Terfloth Gerald J. Process for preparing maytansinol
US7589180B2 (en) 2001-05-11 2009-09-15 Abbott Laboratories Inc. Specific binding proteins and uses thereof
US20100056762A1 (en) 2001-05-11 2010-03-04 Old Lloyd J Specific binding proteins and uses thereof
US20110313230A1 (en) 2001-05-11 2011-12-22 Terrance Grant Johns Specific binding proteins and uses thereof
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6808450B2 (en) * 2002-12-04 2004-10-26 Christopher E. Snow Solar powered heating and ventilation system for vehicle
CA2522700A1 (en) * 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
US7432088B2 (en) 2003-05-08 2008-10-07 Immunogen Inc. Methods for the production of ansamitocins
EP2135619A1 (en) 2003-12-10 2009-12-23 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
WO2006138429A2 (en) 2005-06-16 2006-12-28 The Feinstein Institute For Medical Research Antibodies against hmgb1 and fragments thereof
EP2298815B1 (en) 2005-07-25 2015-03-11 Emergent Product Development Seattle, LLC B-cell reduction using CD37-specific and CD20-specific binding molecules
EP1928503B1 (en) 2005-08-24 2012-10-03 ImmunoGen, Inc. Process for preparing maytansinoid antibody conjugates
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
CN104013956B (zh) 2007-01-25 2018-12-18 达娜-法勃肿瘤研究所公司 抗egfr抗体在治疗egfr突变体介导的疾病中的用途
AU2008227123B2 (en) 2007-03-15 2014-03-27 Ludwig Institute For Cancer Research Ltd. Treatment method using EGFR antibodies and src inhibitors and related formulations
CA2696360C (en) 2007-08-14 2018-11-20 Ludwig Institute For Cancer Research Monoclonal antibody targeting the egfr receptor and uses thereof
WO2009126944A1 (en) 2008-04-11 2009-10-15 Trubion Pharmaceuticals, Inc. Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
PL2437790T3 (pl) 2009-06-03 2019-09-30 Immunogen, Inc. Sposoby sprzęgania
US20110076232A1 (en) 2009-09-29 2011-03-31 Ludwig Institute For Cancer Research Specific binding proteins and uses thereof
CN110251668A (zh) 2010-11-30 2019-09-20 霍夫曼-拉罗奇有限公司 低亲和力血脑屏障受体抗体及其用途
KR20220123130A (ko) 2011-03-29 2022-09-05 이뮤노젠 아이엔씨 일-단계 방법에 의한 메이탄시노이드 항체 접합체의 제조
CA2837169C (en) 2011-05-24 2021-11-09 Zyngenia, Inc. Multispecific complexes comprising angiopoietin-2-binding peptide and their uses
SG11201502429YA (en) 2012-10-04 2015-04-29 Immunogen Inc Use of a pvdf membrane to purify cell-binding agent cytotoxic agent conjugates
BR112015023752B1 (pt) 2013-03-15 2023-11-14 Zyngenia, Inc. Domínio de reconhecimento modular (mrd), complexo compreendendo mrd e cetuximabe, usos do complexo para inibir a angiogênese e tratar câncer e composição farmacêutica compreendendo o dito complexo
AR097306A1 (es) * 2013-08-20 2016-03-02 Merck Sharp & Dohme Modulación de la inmunidad tumoral
SG10202002577XA (en) 2015-09-21 2020-04-29 Aptevo Res & Development Llc Cd3 binding polypeptides
EP3969907A1 (en) * 2019-05-13 2022-03-23 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) * 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) * 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4713352A (en) * 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4444878A (en) * 1981-12-21 1984-04-24 Boston Biomedical Research Institute, Inc. Bispecific antibody determinants
ES521370A0 (es) * 1982-04-12 1985-04-16 Hybritech Inc Un procedimiento para obtener un polidoma.
US4727021A (en) * 1984-06-01 1988-02-23 Sloan-Kettering Institute For Cancer Research Human monoclonal antibodies to cytokeratin
US4962188A (en) * 1985-12-06 1990-10-09 Cetus Corporation Recombinant ricin toxin A chain conjugates

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100497719B1 (ko) * 2002-06-17 2005-06-28 대동공업주식회사 트랙터용 전륜증속 절환용 클러치

Also Published As

Publication number Publication date
US5141736A (en) 1992-08-25
HU896763D0 (en) 1990-02-28
DK666389A (da) 1990-06-28
HUT53153A (en) 1990-09-28
EP0376176A3 (en) 1990-09-05
DK666389D0 (da) 1989-12-22
CA2006408A1 (en) 1990-06-27
EP0376176A2 (en) 1990-07-04

Similar Documents

Publication Publication Date Title
KR900009096A (ko) 이(2)특이적 단클론성 항체, 그의 제조방법 및 용도
CA1243969A (en) Monoclonal antibody to a human carcinoma tumor associated antigen
KR850007979A (ko) 모노클로날항체 및 제조방법
US4863854A (en) Monoclonal antibodies to mucin-like human differentiation antigens
SE8202012L (sv) Humaninterferon-beslektade peptider, antigener, antikroppar och forfarande for framstellning derav
KR840003815A (ko) 효소와 항체의 공유결합에 의해 결합된 접합체의 제조방법
JP2540179B2 (ja) 非還元・非酵素的糖鎖形成蛋白に対するモノクロ―ナル抗体
AU2508492A (en) Sirs vaccine and diagnosis method
KR880006357A (ko) 인터류킨-i에 대한 항체
KR910009284A (ko) 인체 종양 세포 항원에 특이적인 키메라형 생쥐-인체 a10 항체
NO853397L (no) Nye monoklonale antistoffer til glykokonjugater, fremgangsmaate til fremstilling derav og anvendelser av antistoffene.
CA2007506A1 (en) Monoclonal antibodies directed to tumor-associated gangliosides and fucogangliosides and method for production thereof
DK0466818T3 (da) Monoklonalt antistof der genkender et glycoprotein fra mucin-antigen fra membranen af fedtkugler fra human mælk
Horton et al. Expression of red cell specific determinants during differentiation in the K562 erythroleukaemia cell line
DE68906279D1 (de) Fluorkohlenstoffkette enthaltende antigene konjugate.
KR860001593A (ko) 모노클로날 항체의 제조방법
Hubbard et al. Localization of halothane-induced antigen in situ by specific anti-halothane metabolite antibodies.
AU5129690A (en) Anti-human sperm antibody, and its production
KR890007755A (ko) 베타-배열의 n-아세틸뉴라민산을 인지할 수 있는 단일 클론성 항체
KR880010775A (ko) 면역글로로불린 결합체
NO165945B (no) Anvendelse av monoklonalt fukosebindende antistoff (ggf) for fremstilling av et termisk denaturert glykosidisk bindingsrelatert antigen (gra).
EP0184370A3 (en) Monoclonal antibody specific for a mammary tumor cytoplasmic antigen
CA2150497C (en) Inhibitor and anti-inhibitor monoclonal antibodies specific for horseradish peroxidase
ES8700056A1 (es) Procedimiento de producir antigenos relacionados con el enlace glicosidico derivados de cancer.
Suter et al. Differential expression of cell surface antigens of canine keratinocytes defined by monoclonal antibodies.

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid